Evaluation of Herbal Composite for Activity Against Anti-cancer Drug-induced Nephrotoxicity in Wistar Rats
DOI:
https://doi.org/10.37285/ijpsn.2024.17.2.3Abstract
Background: Nephrotoxicity is among the significant side effects and a dose-restriction mechanism for cisplatin treatment. According to recent studies, Oxidative stress and inflammation are the causative agents for acute renal failure on Cisplatin. Curcumin and resveratrol are considered to have potent anti-inflammatory and antioxidant effects. The current investigation aimed to determine whether a composite of curcumin and resveratrol attenuates nephrotoxicity caused by Cisplatin in Wistar rats.
Method: The herbal compound was administered together with 5 mg/kg of cisplatin daily for 10 days with doses of 100 and 400 mg/kg. To evaluate renal damage, serum creatinine, nitrogen in blood urea, Creatinine, and levels of nitrite were measured. The levels of renal malondialdehyde, decreased glutathione levels, catalase, and also the superoxide dismutase enzyme were measured to quantify renal oxidative stress.
Result: Significant oxidative stress, severe inflammation, and nephrotoxicity were all seen after a single dosage of cisplatin. In Wistar rats, a herbal composite treatment significantly reduced inflammation, improved renal function in a dose-dependent manner, reduced oxidative stress, and provided protection from the nephrotoxicity caused by Cisplatin.
Conclusion: The herbal composite of curcumin - and - resveratrol was found to act as a therapeutic adjutant against Cisplatin nephrotoxicity.
Downloads
Metrics
Keywords:
Cisplatin, Nephrotoxicity, Herbal composite, Anti-inflammatory, AntioxidantPublished
How to Cite
Issue
Section
References
Al Fayi M, Otifi H, Alshyarba M, Dera AA, Rajagopalan P. Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling. Journal of Drug Targeting. 2020 Oct 20;28(9):913-22.
Oh GS, Kim HJ, Shen A, Lee SB, Khadka D, Pandit A, So HS. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolytes & Blood Pressure: E & BP. 2014 Dec;12(2):55.
dos Santos NA, Carvalho Rodrigues MA, Martins NM, Dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Archives of toxicology. 2012 Aug;86:1233-50.
Robin S. Goldstein, Gilbert H. Mayor, The nephrotoxicity of cisplatin, Life Sciences, Volume 32, Issue 7,1983 Pages 685-690,
Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. International journal of cancer. 1999 Dec 10;83(6):866-9.
Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer chemotherapy and pharmacology. 2003 Jul;52:13-8.
Cullen KJ, Yang Z, Schumaker L, Guo Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. Journal of bioenergetics and biomembranes. 2007 Feb;39:43-50.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010 Oct 26;2(11):2490-518.
Hirama M, Isonishi S, Yasuda M, Ishikawa H. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncology reports. 2006 Nov 1;16(5):997-1002.
Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, Inoue M. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. American Journal of Physiology-Cell Physiology. 2005 Dec;289(6):C1466-75.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010 Oct 26;2(11):2490-518.
Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. Journal of Clinical Oncology. 2006 Jul 1;24(19):3095-100.
Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Molecular pharmacology. 2004 Oct 1;66(4):817-23.
Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity: insights into mechanism. International journal of andrology. 1987 Feb;10(1):325-46.
Gogas H, Shapiro F, Aghajanian C, Fennelly D, Almadrones L, Hoskins WJ, Spriggs DR. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecologic oncology. 1996 Apr 1;61(1):22-6.
Topcu-Tarladacalisir Y, Sapmaz-Metin M, Karaca T. Curcumin counteracts cisplatin-induced nephrotoxicity by preventing renal tubular cell apoptosis. Renal failure. 2016 Nov 25;38(10):1741-8.
Ugur S, Ulu R, Dogukan A, Gurel A, Yigit IP, Gozel N, Aygen B, Ilhan N. The renoprotective effect of curcumin in cisplatin-induced nephrotoxicity. Renal failure. 2015 Feb 7;37(2):332-6.
Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. American Journal of Physiology-Renal Physiology. 2009 Mar;296(3):F505-11.
Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney international. 1984 May 1;25(5):753-8.
Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. British journal of cancer. 2005 Sep;93(6):678-87.
